Ironwood Pharmaceuticals and Forest Laboratories, Inc. to Host Conference Call to Discuss FDA Approval of LINZESSTM (Linaclotide) for the Treatment of Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation
Published: Aug 31, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) will be hosting a conference call to discuss the U.S. Food and Drug Administration (FDA) approval of LINZESS™ at 4:00 p.m. Eastern Time on Thursday, August 30, 2012. Individuals interested in participating in the call should dial (877) 643-7155 (U.S. and Canada) or (914) 495-8552 (international) using conference ID number 26759985. To access the webcast, please visit the Investors section of Ironwood’s website at www.ironwoodpharma.com or the Forest website at www.frx.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.